Alexandria Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | $215K | Buy |
3,629
+137
| +4% | +$9.02K | 0.02% | 239 |
|
|
2021
Q2 | $233K | Buy |
+3,492
| New | +$228K | 0.02% | 246 |
|
|
2021
Q1 | – | Sell |
-4,128
| Closed | -$256K | – | 259 |
|
|
2020
Q4 | $256K | Sell |
4,128
-630
| -13% | -$38.7K | 0.03% | 225 |
|
|
2020
Q3 | $287K | Sell |
4,758
-10
| -0.2% | -$602 | 0.03% | 207 |
|
|
2020
Q2 | $280K | Buy |
4,768
+215
| +5% | +$12.9K | 0.04% | 204 |
|
|
2020
Q1 | $254K | Sell |
4,553
-393
| -8% | -$24K | 0.04% | 199 |
|
|
2019
Q4 | $317K | Buy |
4,946
+560
| +13% | +$32.1K | 0.04% | 208 |
|
|
2019
Q3 | $222K | Buy |
+4,386
| New | +$206K | 0.03% | 226 |
|
|
2019
Q2 | – | Sell |
-4,386
| Closed | -$210K | – | 259 |
|
|
2019
Q1 | $210K | Hold |
4,386
| – | – | 0.03% | 246 |
|
|
2018
Q4 | $228K | Buy |
4,386
+846
| +24% | +$45.5K | 0.04% | 230 |
|
|
2018
Q3 | $219K | Sell |
3,540
-7,360
| -68% | -$437K | 0.03% | 219 |
|
|
2018
Q2 | $603K | Sell |
10,900
-279
| -2% | -$15.1K | 0.09% | 162 |
|
|
2018
Q1 | $707K | Buy |
11,179
+110
| +1% | +$7.08K | 0.1% | 152 |
|
|
2017
Q4 | $678K | Buy |
11,069
+10,268
| +1,282% | +$642K | 0.1% | 156 |
|
|
2017
Q3 | $51K | Sell |
801
-101
| -11% | -$5.9K | 0.01% | 235 |
|
|
2017
Q2 | $50K | Buy |
902
+1
| +0.1% | +$54 | 0.01% | 233 |
|
|
2017
Q1 | $49K | Buy |
901
+340
| +61% | +$18.6K | 0.01% | 229 |
|
|
2016
Q4 | $33K | Sell |
561
-869
| -61% | -$47.5K | 0.01% | 292 |
|
|
2016
Q3 | $78K | Buy |
1,430
+800
| +127% | +$51.4K | 0.01% | 201 |
|
|
2016
Q2 | $46K | Buy |
630
+15
| +2% | +$1.06K | 0.01% | 258 |
|
|
2016
Q1 | $39K | Buy |
615
+15
| +3% | +$946 | 0.01% | 273 |
|
|
2015
Q4 | $41K | Buy |
+600
| New | +$39.6K | 0.01% | 278 |
|
|
2015
Q2 | – | Sell |
-564
| Closed | -$36K | – | 605 |
|
|
2015
Q1 | $36K | Sell |
564
-177
| -24% | -$11.1K | 0.01% | 235 |
|
|
2014
Q4 | $44K | Buy |
741
+72
| +11% | +$4.06K | 0.02% | 205 |
|
|
2014
Q3 | $34K | Sell |
669
-23
| -3% | -$1.15K | 0.01% | 234 |
|
|
2014
Q2 | $34K | Sell |
692
-67
| -9% | -$3.3K | 0.01% | 243 |
|
|
2014
Q1 | $39K | Buy |
759
+67
| +10% | +$3.56K | 0.02% | 229 |
|
|
2013
Q4 | $37K | Hold |
692
| – | – | 0.02% | 236 |
|
|
2013
Q3 | $32K | Sell |
692
-2,000
| -74% | -$87.8K | 0.01% | 255 |
|
|
2013
Q2 | $120K | Buy |
+2,692
| New | +$117K | 0.06% | 133 |
|
Other funds holding BMY
Alexandria Capital's BMY Position: Q3 2021 in Review
Alexandria Capital increased its Bristol-Myers Squibb (BMY) stake by 3.9% in Q3 2021, buying an estimated $9.02K and bringing the position to 3,629 shares worth $215K. The position accounts for 0.02% of the portfolio, ranked #239.
Alexandria Capital first reported a position in BMY in Q2 2013 and has held it in 30 quarters since. The position peaked at $707K in Q1 2018. 2,293 funds tracked by Wall St. Rank hold BMY as of Q3 2021.
- Alexandria Capital held 3,629 shares of Bristol-Myers Squibb worth $215K as of Q3 2021.
- Alexandria Capital bought 137 Bristol-Myers Squibb shares in Q3 2021, an estimated $9.02K.
- Bristol-Myers Squibb made up 0.02% of Alexandria Capital's portfolio in Q3 2021, its #239 holding.
- Alexandria Capital first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 30 quarters since.
- Alexandria Capital's Bristol-Myers Squibb position peaked at $707K in Q1 2018.
- 2,293 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2021.
Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.